An analysis of relapse and risk factors of autoimmune hemolytic anemia and Evans syndrome.
- Author:
Hong LIU
1
;
Zong-hong SHAO
;
Zhen-zhu CUI
;
Yu-hong WU
;
Tie-jun QIN
;
Rong FU
;
Guang-sheng HE
;
Jun SHI
;
Jie BAI
;
Yan-ran CAO
;
Chong-li YANG
;
Tian-ying YANG
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Anemia, Hemolytic, Autoimmune; etiology; immunology; Autoantibodies; blood; Child; Cyclosporine; therapeutic use; Female; Humans; Male; Middle Aged; Prednisone; therapeutic use; Recurrence; Risk Factors; Syndrome; Thrombocytopenia; etiology; immunology
- From: Chinese Journal of Hematology 2003;24(10):534-537
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo analyse the relapse rate and risk factors of autoimmune hemolytic anemia (AIHA) and Evans syndrome.
METHODSFifty two cases of AIHA and Evans syndrome in remission being followed up for 1 - 14 years (median time 3.8 years) were analysed for relapse rate. The risk factors of relapse were analysed by case-control study.
RESULTSThe total relapse rate of these AIHA and Evans syndrome patients was 57.7%, and the median remission duration to the first relapse was 9 months. The relapse rates in patients with negative Coombs test, warm autoantibodies and both of warm and cold autoantibodies were 30.8% (4/13), 54.0% (13/24) and 86.7% (13/15), respectively. The relapse rate in patients with cold antibody was the highest (P < 0.05). The relapse rate in patients with antibody titer >or= 100 was 92.9% (13/14) and was higher than that in patients with antibody titer < 100 [59.5% (13/22)] (P < 0.05). Patients treated with prednisone and cyclosporin relapsed less than those treated with prednisone alone, and the relapse was related to the therapy course of prednisone and CsA.
CONCLUSIONBecause of the high relapse rate, AIHA and Evans syndrome should be treated according to the class of autoantibodies, and with longer course of prednisone and cyclosporin and prophylaxis of infection.
